Navigation Links
PAREXEL Announces Date of Second Quarter Fiscal Year 2012 Earnings Release and Conference Call
Date:1/3/2012

BOSTON, Jan. 3, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) will release financial results for the Second Quarter of Fiscal Year 2012 on Monday, January 30, 2012 after the close of the stock market.  The announcement will be available on PAREXEL's website at www.PAREXEL.com and on the PR Newswire website at www.prnewswire.com.

PAREXEL will host a conference call and live webcast at 10:00 a.m. ET on Tuesday, January 31, 2012 to discuss the results.  To access the webcast, visit PAREXEL's website at www.PAREXEL.com, and click on the Investors menu.  This webcast will continue to be accessible for one year following the live broadcast.  To participate via telephone, dial (408) 940-3886 and ask to join PAREXEL's Second Quarter Fiscal Year 2012 conference call.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 67 locations throughout 52 countries around the world, and has approximately 10,850 employees.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

Contacts:
James Winschel, Senior Vice President and Chief Financial Officer
Jill Baker, Corporate Vice President, Investor Relations
+1-781-434-4118
Email: Jill.Baker@PAREXEL.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
2. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
3. UCB and PAREXEL Sign Strategic Partnership Agreement
4. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
5. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
6. PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results
7. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
8. New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
9. PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent
10. PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call
11. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 12, 2017   Divoti USA will engrave ... the standard of the latest FDA requirements, which stipulates new criteria ... Anyone in need of Medical ID jewelry such as Medical ID ... are engraved in terms of the new FDA requirements . ... Divoti offers this dark mark ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
Breaking Medicine News(10 mins):